Navigation Links
PharmaNet Development Group Symposia 'Crossing the Bridge from Preclinical to Clinical Studies' to be Held February 2010 in Basel, Dusseldorf and Vienna

PRINCETON, N.J., Jan. 11 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, is pleased to announce that it is hosting a complementary symposium and round table discussion entitled "Crossing the Bridge from Preclinical to Clinical Studies".

Recently, the Company successfully hosted a similar symposium in Sweden. Due to its success, the Company will be hosting the event in other important biotechnology centers in Europe. The symposia will be held in:

Basel, Switzerland on 9 February 2010

Dusseldorf, Germany on 10 February 2010

Vienna, Austria on 11 February 2010

Robert Reekie, Senior Executive Vice President, Europe and Asia-Pacific, said, "This symposium demonstrates PharmaNet's commitment to the European Biotech sector and the expertise that we can bring to clinical programs as we assist biopharmaceutical companies commercialise their products efficiently."

Whether facing complex regulatory requirements, conducting first-in-man studies, or developing clinical development plans for late stage clinical trials, PharmaNet senior-level professionals assist biopharmaceutical companies in navigating this critical stage of drug development. With established credentials, proven experience, and insight acquired through working with international regulatory agencies, PharmaNet provides viable strategies to conduct studies from Phase I through Phase IV utilizing its global network of resources.

For Phase I clinical development, the Company's clinics have more than 300 beds and access to numerous special populations. For Phase II-IV clinical development programs, PharmaNet conducts studies in virtually all therapeutic areas, including oncology, cardiology, dermatology, infectious diseases, neurosciences, ophthalmology, women's health, pediatrics, and Phase IV development.

Robert Reekie will chair the symposia. Other PharmaNet experts will discuss innovative approaches to concept testing and market authorization including the following topics:

  • New Scientific and Regulatory Approaches for Flexible Design of Early Stage Trials and Their Preclinical Support, Bengt R. Danielsson, MD, PhD, Vice President, PharmaNet Consulting
  • Overview on Global Approaches for Scientific Advice and Regulatory Submissions, Franz Buchholzer, PhD, Vice President, Worldwide Regulatory Operations
  • Strategies for Effective Drug Development, Gregory M Hockel, PhD, Executive Vice President, Worldwide Regulatory Operations
  • Designing Safe and Efficient Phase I Studies, Mario Tanquay, PhD, BPharmSc, Vice President, Scientific & Regulatory Affairs
  • Arriving to the Clinical Side: Trial Design Considerations, Jeff Freitag, MD, Senior Vice President, PharmaNet Consulting

To attend the conference, please contact Klaus Haller at +49 8989557755 or by email

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at

    Contact: Patricia Hall
    Phone: +44 1494 896202

SOURCE PharmaNet Development Group, Inc.

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
2. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
3. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
4. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
5. Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude(TM) SkinPrep System
6. WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
7. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
8. Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
9. Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR)
10. Vivakor Signs Business Development Agreement With Baker Consulting
11. EDP Biotech Takes Next Step in the Development of ColoMarker
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):